BL is an entrepreneur and an excellent PR specialist. If it wasn't for him RAP would have been flying under the radar and not hit a high of 55 cents per share IMO. It was him that sold the idea to FIL who is currently capped at a 10% shareholding in RAP. Sold the idea to many funds, got us on national television on several occasions, many publications have been published through various sources because of him. He does more work behind the scenes for us then a lot of us think.. When he was on board ALC it shot up to 15 cents from memory after he bought in around the 4 cent level, that wasn't by chance his got huge connections in the PR space... His new venture will succeed too because his the man! That idea was sold (oversubscribed) to many investors in the space of two hours the other day! Just incredible! At the end of the day it's up to him what he does with his money no matter how much we like it or not. He founded this company and I can assure you is still very passionate about ResApp. He has an extremely big incentive to get this over the line in order for his 'free' shares to be released to him, a HUGE insensitive for him to push RAP to succeed...
Some have been curious regarding the numbers required to fill up the other three buckets (including myself) for pneumonia etc it all comes down to what the CE, TGA deem as statistically significant. To my knowledge CE mark & TGA clearance is typically easier to obtain than FDA because their focus is on the safety of the device. FDA focus tends to be more on the reassurance that device works as well as safety. Which is why the test subject numbers are far less then the US test subject numbers for statistical significance. I've been doing some research on statistical significance and I came across various websites and chat groups that provide some interesting information. I've come to a conclusion that around 80 test subjects per respiratory disease would be a good number. So our company is aiming to identify 8 different respiratory diseases being:
"Target numbers of patients for lower respiratory tract disease,
lower respiratory tract infection, asthma/reactive airway disease and bronchiolitis have been exceeded. Recruitment will continue in July to increase the number of patients with
pneumonia, croup and upper respiratory tract infection to target levels."
( Information above is found in latest ASX announcement)
8 x 80 = 640 (IMO 200 per respiratory disease for FDA statistical significance) currently we are sitting at 603 test subject. "Study will continue in July" I'm thinking around the 2nd week of July we should have these numbers. Lots of people I know at the moment have the flu etc. the Void will be full in no time!
PS Australian study results will still come out before US results and we will definitely go into a trading halt prior to the release the Australian double blind study results but very unlikely to go into a voluntary suspension...
Happy investing!
Cheers
Red bar
